Intrabiotics

Intrabiotics

Transcript

2. Confidential RAMOPLANIN Oral/VREF Ointment/MSRA PROTEGRINS Rinse/Oral Mucositis Aerosol/Respiratory R&D Pipeline Preclinical Pipeline Clinical Pipeline Technology Acquisitions & Research Approval Intravenous Fungal Intravenous Antibacterial
3. Confidential Q3 Q4 Q1 Q2 Clinical Momentum Protegrin Aerosol / Respiratory Infections Protegrin Rinse / Oral Mucositis Ramoplanin Ointment / MRSA 1999 1998 Ramoplanin Oral / VREF Phase II Ph I Year-End 1998 Phase II Phase II Phase II Phase I
4. Confidential VREF Intestinal: Phase I Before Ramoplanin Day 4 Day 10 Detection Limit Enterococci/gm 6.3 3.3 3.3 10 6 10 4 10 2 10 0 10 1 10 3 10 5 10 7 Days of Ramoplanin Ramoplanin
5. Confidential Ramoplanin Ointment / MRSA: Preclinical Efficacy 0 30 60 90 120 150 180 210 240 Minutes Mupirocin Ointment 0 1 2 3 4 5 6 10 10 10 10 10 10 10 Ramoplanin Number Bacteria / mL Ramoplanin Ointment
6. Confidential 100 75 50 25 0 Untreated Treated Organisms per swab (1000s) Protegrin IB-367 Rinse / Oral Mucositis: Phase I Well tolerated, antimicrobial efficacy Protegrin
7. Confidential Protegrin Partner: Pharmacia & Upjohn   Focus –  Oral mucositis –  Additional indications   IntraBiotics is lead developer in U.S. –  50% reimbursement of development expenses –  Co-promotion for infectious disease uses –  50/50 profit sharing   P&U leads development ex-U.S. –  Pursue with diligence –  High royalty and manufacturing margins plus   Clinical milestones, equity and license fee
8. Confidential Number Bacteria / mL 0 10 20 30 40 50 60 120 Minutes Placebo Tobramycin Protegrin IB-367 Aerosol / Respiratory: Preclinical Protegrin IB-367 0 1 2 3 4 5 7 6
9. Confidential Ramoplanin Ointment / MRSA: Preclinical Efficacy 0 30 60 90 120 150 180 210 240 Minutes Mupirocin Ointment 0 1 2 3 4 5 6 10 10 10 10 10 10 10 Ramoplanin Number Bacteria / mL Ramoplanin Ointment
10. Confidential Q3 Q4 Q1 Q2 Q3 Q4 Clinical Momentum Phase III Protegrin Aerosol / Respiratory Infections Protegrin Rinse / Oral Mucositis Ramoplanin Ointment / MRSA Phase III 2000 2001 1999 1998 Ramoplanin Oral / VREF Phase II Phase III NDA Ph I Creating Near-Term Value Phase II Phase II Phase II Phase I Phase III NDA NDA NDA Phase III
11. Confidential Management Team Team Member Kenneth Kelley John Fiddes, Ph.D. Henry Fuchs, M.D. Janet Swearson Karen Campbell Position President and CEO VP, R&D VP, Clinical Affairs VP, Finance and CFO VP, Marketing Past Company Institutional Venture Partners ImmuLogic Genentech Affymax Roche Laboratories
12. Confidential MCDE PCYC VRTX AVIR AGPH IB Today IB Q1, 1999 IB Q4, 1999 IB 2001 0 100 200 300 400 500 600 700 800 900 Valuation ($000's) Market Capitalization vs. Development Stage Research Phase I Phase II Phase III NDA Filed Product Sales
13. Confidential MCDE PCYC VRTX AVIR AGPH IB Today IB Q1, 1999 IB Q4, 1999 IB 2001 0 100 200 300 400 500 600 700 800 900 Research Phase I Phase II Phase III NDA Filed Product Sales Valuation ($000's) Market Capitalization vs. Development Stage
14. Confidential U.S. and Europe Market Opportunities Time to Market $6.0 Billion Total $200M $1.8B $2B $800M $600M $600M Ramoflavin Oral for VREF Protegrin Rinse for Oral Mucositis Protegrin Aerosol for Respiratory Infections Ramoplanin Ointment for MSRA Intravenous Antibacterial Intravenous Antifungal
15. Confidential Three-Year Outlook: 2001 Significant Increase in Shareholder Value Diverse Pipeline Integrated Business 2 Products Launched in U.S. Near Term Profitability
16. Confidential Three-Year Outlook: 2001 Significant Increase in Shareholder Value Diverse Pipeline Integrated Business 2 Products Launched in U.S. Near Term Profitability Late Stage Clinical Products From Research to Sales Breakthrough Therapies Product Revenues and Partnerships